Lorem ipsum dolor sit amet, consectetur adipiscing elit,
In the last week, the FDA approved the first maternal vaccine designed to safeguard infants from respiratory syncytial virus (RSV) during the critical period immediately from birth up to 6 months of age, when they
View More
Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo effects within central nervous
View More Tampa, Florida, July 26, 2023 /GlobeNewswire/ — CenExel FCR has been named the 2023 Tampa Bay Times People’s Choice, Best of the Best in Clinical Research. This remarkable achievement
View More Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July
View More CenExel is proud to announce the publication of the work of Brett English, PharmD, PhD, from CenExel's Clinical Sciences team, in the Neurogastroenterology & Mortility journal. Dr. English participated
View More [et_pb_section fb_built=”1″ _builder_version=”4.12.0″ global_colors_info=”{}”][et_pb_row _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel
View More [et_pb_section fb_built=”1″ _builder_version=”4.12.0″ global_colors_info=”{}”][et_pb_row _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.12.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”] Salt Lake City, November 15, 2022 /GlobeNewswire/ — CenExel announces
View More Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
View More Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig Goenjian, have developed fit
View More General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson & Gotzsche, 2001). The high
View More
